Who is eligible for clinical trial NCT02970318?

Participants must meet protocol criteria for Chronic Lymphocytic Leukemia. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT02970318 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-22

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL (NCT02970318)

A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Acerta Pharma BV

🩺 Plain-English Summary (8th-Grade Level)

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Who can join: Review the eligibility criteria below.

Location: Research Site — Chandler, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (157 Sites)

Showing the first 25 of 157 sites.

Research Site — Chandler, Arizona
Research Site — Oxnard, California
Research Site — Athens, Georgia
Research Site — Joliet, Illinois
Research Site — Cedar Rapids, Iowa
Research Site — Mount Sterling, Kentucky
Research Site — Saint Cloud, Minnesota
Research Site — Lincoln, Nebraska
Research Site — Brick, New Jersey
Research Site — Nyack, New York
Research Site — Canton, Ohio
Research Site — Fort Sam Houston, Texas
Research Site — Round Rock, Texas
Research Site — Adelaide,
Research Site — Box Hill,
Research Site — Frankston,
Research Site — Geelong,
Research Site — Gosford,
Research Site — Hobart,
Research Site — Kogarah,
Research Site — Murdoch,
Research Site — Nedlands,
Research Site — South Brisbane,
Research Site — Woodville,
Research Site — Linz,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Lymphocytic Leukemia

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) — Anchorage, Alaska
Economic Analysis of Alliance A041202 CLL Study — Calgary, Alberta
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Phoenix, Arizona

Explore by condition: All Chronic Lymphocytic Leukemia clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗